The Australian Patent Office has awarded BioCurex Inc. its first patent to develop applications of its proprietary RECAF technology to therapy. The approval is a sequel of the first approval to diagnostic application that was a part of the original filing. The company owns the technology to use RECAF, a molecule which is present inside and on the surface of cancer cells. These cells release some RECAF into the blood stream. This has led to the development of a blood test for cancer which can successfully diagnose about 90% of patients with malignancies with precision.